Translate
Subscribe to Blog via Email
Ronny Allan
Summary
Great start to 2023 and I thank those who continue to support my social media and this blog. I’m keen to hear any suggestions of the sort of thing you would like me to research and publish.
The top 10 most-read posts in January are listed below:
Paul Hunter Tribute – Snooker champion and Neuroendocrine Cancer patient
The Masters Snooker competition was held in January 2023 and there was a tremendous spike in views at the time of the final. The Masters Trophy was named the Paul Hunter trophy, and this incidentally generates a vast amount of awareness for Neuroendocrine Cancer as most of the hits come from outside the Neuroendocrine community. Click here or on the picture.
Cancer Ablation
A popular post with the headline of the new equipment that can handle liver tumours up to 2.4cm. Click here or on the picture:
Dustin Diamond
My latest blog post about the cancer that killed him
Click here or on the picture to read more.
Irrfan Khan
Famous Indian actor whose birthday was on 7th Jan. Click here or on the picture to read more.
Diagnosed with Neuroendocrine Cancer? – 10 questions to ask your doctor (and where to find a NET Specialist Worldwide)
This post is likely to be in the top 10 every month! Click here or on the picture to read more.
Lactose Intolerance – The NET Effect
I wasn’t milking this post, it’s an interesting subject with linkages to surgery in NET.
Neuroendocrine tumors are uncommon but definitely not rare
The worst-kept secret ever but the USA is jumping on board (officially). Click here or on the picture to read more.
Cancer-related fatigue (CRF) – Neuroendocrine Cancer
A common symptom but deconflicting between regular tiredness and fatigue and something caused by cancer is difficult.
Click here or on the picture to read.
Currently trending on RonnyAllan.NET
If you need a catch-up, this is the place to go. It updates what is being read most on my website in the last 48 hours and automatically updates.
Click here or on the picture to read more.
EUS Guided Ablation for small pancreatic NETs (Less than 2cm)
I think this is something to be discussed more in 2023. Click here or on the picture to read more.
Previous 2 months updates
RonnyAllan.NET – Summary of December 2022 – Ronny Allan – Living with Neuroendocrine Cancer
Click here or on the picture to read more.
RonnyAllan.NET – Summary of November 2022 – Ronny Allan – Living with Neuroendocrine Cancer
Click here or on the picture to read more.
Disclaimer
I am not a doctor or any form of medical professional, practitioner or counsellor. None of the information on my website, or linked to my website(s), or conveyed by me on any social media or presentation, should be interpreted as medical advice given or advised by me.
Neither should any post or comment made by a follower or member of my private group be assumed to be medical advice, even if that person is a healthcare professional.
Please also note that mention of a clinical service, trial/study or therapy does not constitute an endorsement of that service, trial/study or therapy by Ronny Allan, the information is provided for education and awareness purposes and/or related to Ronny Allan’s own patient experience. This element of the disclaimer includes any complementary medicine, non-prescription over the counter drugs and supplements such as vitamins and minerals.
Top 10 Posts & Pages in the last 48 hours (auto updates) (Click the titles to read them)
Thanks for reading.
Personal Facebook. Like this page please.
Blog Facebook. Like this page please.
Awareness Facebook Like this page please.
Sign up for my newsletters – Click Here
My Diagnosis and Treatment History
Check out my online presentations
Check out my WEGO Health Awards
Check out my Glossary of Terms – click here
Please Share this post for Neuroendocrine Cancer awareness and to help another patient
Neuroendocrine Cancer Clinical Trial – Lutetium-177Lu (Satoreotide)
What is Satoreotide? It’s an agonist treatment. i.e. a ‘next generation’ radiologand for Peptide receptor radionuclide therapy (PRRT) or more specifically the radiopharmaceutical that binds
A review of September 2023 on RonnyAllan.NET – Living with Neuroendocrine Cancer
On my website RonnyAllan.NET, September was an interesting month because I had pushed out some blogs before I went on a planned overseas holiday from
Never mind the Bollocks – here’s the cancer
I don’t tend to share some very personal stuff, but this is on the boundary of that rule and there are some important messages to
First and only FDA-cleared, fully automated chromogranin A assay
There has been controversy about the utility of Chromogranin A for many years now. Specialists have been critical about its use but to be fair
Neuroendocrine Cancer: Question, Clarify, Confirm
One of the many observations I make in my private Neuroendocrine Cancer Facebook group is the misunderstandings caused by the use of non-standard terminology combined
Clinical Trial – Lutathera NETTER-2 Important Update
UPDATE – Sep 25th, 2023 – Novartis radioligand therapy Lutathera® demonstrated statistically significant and clinically meaningful progression-free survival in first line advanced gastroenteropancreatic neuroendocrine tumors
Lanreotide: Ipsen injection devices vs generic injection devices
Whenever I get a chance to talk to a pharma involved in somatostatin analogue injection devices, I tell them one very important thing …… “To
Cancer doesn’t take holidays (but I do)
Glen Etive Scotland in 2018 After diagnosis in July 2010, with the exception of a planned holiday to Turkey prior to my ‘big surgery’, holidays
Update from Ronny Allan: No evidence of progressive disease at any site
Update August 2023. Latest CT surveillance scan reports “No evidence of progressive disease at any site”. Very pleased! With incurable but treatable cancers such as
